French To Review The ‘Gamble’ Of Early Access Decisions

 
• By Ian Schofield

The Haute Autorité de Santé says that the risk of granting early access may only be justifiable if uncertainties over the clinical benefit of a drug can be addressed within a “reasonable” timeframe.

many question marks from the screen of tablet computer,
Early access schemes involve uncertainties over the clinical evidence • Source: Shutterstock

More from Europe

More from Geography